Orange Book product · Brand (NDA)
DEXILANT SOLUTAB
DEXLANSOPRAZOLE
At a glance
Jan 26, 2016
Approved
Brand (NDA)
Application
Not listed
TE code
7
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jan 26, 2016
10 yr 7 mo ago
Patent 8461187 expires
Listed drug product patent expiration.
Jan 17, 2026
5 mo ago
Patent 9238029 expires
Listed drug product patent expiration.
Jan 17, 2026
5 mo ago
Patent 9011926 expires
Listed drug product patent expiration.
Feb 24, 2026
4 mo ago
Today
Patent 8461187*PED expires
Listed listed patent expiration.
Jul 17, 2026
in 28 d
Patent 8871273 expires
Listed drug product patent expiration.
Jan 11, 2028
in 1 yr 7 mo
Patent 8871273*PED expires
Listed listed patent expiration.
Jul 11, 2028
in 2 yr 1 mo
Patent 9241910 expires
Listed drug product patent expiration.
Mar 10, 2029
in 2 yr 9 mo
Pharmaceutical detail
Active ingredient
DEXLANSOPRAZOLE
Strength
30MG
Dosage form
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
Route
ORAL
TE code
Not listed
Application
NDA 208056
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (7)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8461187 | Jan 17, 2026 | 5 mo ago | Product |
| 9238029 | Jan 17, 2026 | 5 mo ago | Product |
| 9011926 | Feb 24, 2026 | 4 mo ago | Product |
| 8461187*PED | Jul 17, 2026 | in 28 d | |
| 8871273 | Jan 11, 2028 | in 1 yr 7 mo | Product |
| 8871273*PED | Jul 11, 2028 | in 2 yr 1 mo | |
| 9241910 | Mar 10, 2029 | in 2 yr 9 mo | Product |
